Mergers and Acquisitions - Weixing New Materials plans to acquire 88.2557% equity of Beijing Songtiancheng Technology Co., Ltd. for 111 million yuan, focusing on the development, manufacturing, and sales of polyethylene valves for municipal pipeline networks [1] - Yunnan City Investment intends to publicly transfer 10.5% equity of Kunming Qicai Yunnan Urban Construction Investment Co., Ltd. with a base price of 293 million yuan [2] Shareholding Changes - Pengling Co., Ltd.'s actual controller Wang Zhifang plans to increase his shareholding by 20 million to 40 million yuan within six months, reflecting confidence in the company's business transformation and long-term investment value [3] - Anji Food's controlling shareholder Lin Xiaofang intends to reduce his stake by up to 3%, amounting to a maximum of 705,600 shares, due to personal funding needs [4] - Zhongqi New Materials' shareholder Zhou Jun and his concerted action party plan to reduce their holdings by up to 3% of the company's shares [5] Earnings Forecasts - Guocheng Mining forecasts a net profit attributable to shareholders of 1 billion to 1.12 billion yuan for 2025, compared to a profit of 453 million yuan in the same period last year [6] - Palm Shares anticipates a net loss of 1 billion to 1.2 billion yuan for 2025 [7] - Daoshi Technology expects a net profit attributable to shareholders of 480 million to 580 million yuan for 2025, representing a year-on-year growth of 206.01% to 269.76% [8] Risk Matters - Zhongbai Group received a warning letter from the Hubei Securities Regulatory Bureau due to untrue financial data disclosures and failure to timely disclose litigation and arbitration amounts exceeding 10% of the latest audited net assets [9] - Ruiang Gene's actual controllers Xiong Hui and Xiong Jun have been prosecuted for fraud, following their earlier arrest [10]

Core Viewpoint - Ruiang Gene (688217.SH) announced that its actual controllers, Ms. Xiong Hui and Mr. Xiong Jun, have been arrested on charges of fraud, and the prosecution has initiated legal proceedings against them [1] Group 1 - The company received notification from the family of the actual controllers regarding the legal actions taken against them [1] - Ms. Xiong Hui and Mr. Xiong Jun are currently not serving as directors or senior management personnel in the company [1] - The ongoing legal matters are not expected to have a significant adverse impact on the company's daily operations [1]

Core Viewpoint - The actual controllers of Ruian Gene, Ms. Xiong Hui and Mr. Xiong Jun, have been arrested for fraud and are now facing litigation initiated by the prosecution [1] Company Impact - Ms. Xiong Hui and Mr. Xiong Jun are no longer serving as directors or senior management personnel in the company [1] - The ongoing legal issues are not expected to have a significant adverse impact on the company's daily operations [1]

Core Viewpoint - Ruiang Gene forecasts an annual revenue of 170 million to 176 million yuan for 2025, indicating a significant decline in profit due to various factors [1] Group 1: Revenue and Profit Decline - The company expects a revenue decrease of approximately 66.31 million to 72.31 million yuan in 2025, representing a year-on-year decline of 27.36% to 29.84% [1] - The decline in revenue has led to a reduction in gross profit [1] Group 2: Factors Contributing to Decline - Increased competition in the in vitro diagnostics industry and specific events affecting the company have negatively impacted revenue [1] - Slower payment collection from downstream clients due to the medical industry environment has resulted in increased provisions for credit impairment losses on accounts receivable [1] - The suspension of the molecular diagnostic reagent R&D center and industrialization project, with no plans for resumption, has led to impairment losses being recognized [1] - Performance declines in subsidiaries Shanghai Yuanqi Bio and Wuhan Baitai have prompted the company to recognize goodwill impairment losses and asset impairment losses, respectively, due to changes in the external market environment [1] Group 3: Tax Asset Adjustments - The significant decline in performance for both the parent and subsidiary companies has led to a reassessment of future taxable income, resulting in the write-off of previously recognized deferred tax assets [1]

Core Viewpoint - The actual controllers of Ruian Gene, Ms. Xiong Hui and Mr. Xiong Jun, have been arrested for fraud and are facing legal proceedings, but this situation is not expected to significantly impact the company's daily operations [1] Company Operations - The actual controllers, Ms. Xiong Hui and Mr. Xiong Jun, are no longer serving as directors or senior management, ensuring that the company’s daily operations remain unaffected [1] - The company has a robust corporate governance structure and internal control system in place, with clear processes to ensure operational management [1] - The executive team is currently managing the company's operations normally, and all directors and senior management are fulfilling their duties as expected [1] - Business activities are continuing as normal, indicating stability in the company's operational performance [1]

人民财讯1月23日电，睿昂基因(688217)1月23日公告，前期，公司实际控制人熊慧、熊钧因涉嫌诈骗罪 已被批捕。近日，公司收到实际控制人熊慧、熊钧家属的通知，实际控制人熊慧、熊钧因涉嫌诈骗罪已 被检察机关向法院提起诉讼。目前，公司业务正常开展，经营活动正常进行。睿昂基因同日公告，预计 2025年度实现归属于母公司所有者的净利润为亏损3990.69万元到5986.03万元。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海睿昂基因科技股份有限公司董事会 2026 年 1 月 24 日 前期，公司实际控制人熊慧女士、熊钧先生因涉嫌诈骗罪已被批捕。近日， 公司收到实际控制人熊慧女士、熊钧先生家属的通知，实际控制人熊慧女士、熊 钧先生因涉嫌诈骗罪已被检察机关向法院提起诉讼。 熊慧女士、熊钧先生目前未在公司担任董事或高级管理人员职务，上述事项 不会对公司日常经营活动产生重大不利影响。公司具备完善的法人治理结构与内 部控制体系，各项经营管理工作均有明确的流程保障，公司日常经营管理由高管 团队负责，董事及高级管理人员目前均正常履职。目前，公司业务正常开展，经 营活动正常进行。 公司将持续关注上述事项的进展情况，并严格按照有关法律、法规的规定和 要求，及时履行信息披露义务。公司指定信息披露媒体为《上海证券报》《中国 证券报》《证券时报》《证券日报》及上海证券交易所网站（www.sse.com.cn）， 公司发布的信息均以在上述指定媒体披露的信息为准，敬请广大投资者理性投资， 并注意投资风险。 特此公告。 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2026-001 上海睿昂基因科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 二、上年同期业绩情况 （一）2024 年度，公司实现营业收入为 24,230.62 万元；实现利润总额为 -2,847.45 万元；实现归属于母公司所有者的净利润为-1,576.45 万元；归属于母 公司所有者的扣除非经常性损益的净利润为-1,924.76 万元。 （二）每股收益：-0.28 元/股。 三、本期业绩变化的主要原因 报告期内，公司实现归属于母公司所有者的净利润和归属于母公司所有者的 扣除非经常性损益的净利润同比出现较大幅度的下滑，主要有以下四个方面的原 因： （二）业绩预告情况 1、经财务部门初步测算，上海睿昂基因科技股份有限公司（以下简称"公 司"）预计 2025 年年度实现营业收入 17,000.00 万元至 17,600. ...

格隆汇1月23日丨睿昂基因(688217.SH)公布，公司预计2025年年度实现归属于母公司所有者的净利润将 出现亏损，实现归属于母公司所有者的净利润为-3,990.69万元到-5,986.03万元。公司预计2025年年度实 现归属于母公司所有者的扣除非经常性损益的净利润为-4,990.69万元至-6,986.03万元。 ...

Core Viewpoint - Ruiang Gene has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expected losses ranging from 39.91 million to 59.86 million yuan, primarily due to intensified competition in the in vitro diagnostics industry and other adverse factors [1] Group 1: Financial Performance - The company anticipates a decrease in operating revenue for 2025, projected to fall between 66.31 million and 72.31 million yuan, representing a year-on-year decline of approximately 27.36% to 29.84% [1] - The net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show a substantial decline compared to the previous year [1] Group 2: Contributing Factors - The decline in revenue is attributed to intensified competition in the in vitro diagnostics sector and specific adverse events affecting the company [1] - The company has increased provisions for credit impairment losses on accounts receivable due to slower payment from downstream customers influenced by the medical industry environment [1] - The company has recognized impairment losses on its molecular diagnostic reagent R&D center and industrialization project, which has been suspended with no plans for resumption [1] - Impairment losses have also been recognized for subsidiaries Shanghai Yuanqi Bio and Wuhan Baitai due to further declines in their performance and indications of asset impairment [1] - The overall performance decline of both the parent and subsidiary companies has led to a reassessment of future taxable income, resulting in the write-off of previously recognized deferred tax assets [1]